CA2505368C - Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same - Google Patents

Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same Download PDF

Info

Publication number
CA2505368C
CA2505368C CA2505368A CA2505368A CA2505368C CA 2505368 C CA2505368 C CA 2505368C CA 2505368 A CA2505368 A CA 2505368A CA 2505368 A CA2505368 A CA 2505368A CA 2505368 C CA2505368 C CA 2505368C
Authority
CA
Canada
Prior art keywords
compound
solution
product
compounds
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2505368A
Other languages
English (en)
French (fr)
Other versions
CA2505368A1 (en
Inventor
Yong Li
Kurt Sundermann
Li Tang
David Myles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of CA2505368A1 publication Critical patent/CA2505368A1/en
Application granted granted Critical
Publication of CA2505368C publication Critical patent/CA2505368C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2505368A 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same Expired - Fee Related CA2505368C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42535202P 2002-11-07 2002-11-07
US60/425,352 2002-11-07
US47374303P 2003-05-27 2003-05-27
US60/473,743 2003-05-27
PCT/US2003/035411 WO2004043954A2 (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same

Publications (2)

Publication Number Publication Date
CA2505368A1 CA2505368A1 (en) 2004-05-27
CA2505368C true CA2505368C (en) 2011-09-20

Family

ID=32314587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2505368A Expired - Fee Related CA2505368C (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same

Country Status (14)

Country Link
US (2) US20040152708A1 (enExample)
EP (3) EP2135868A1 (enExample)
JP (3) JP4641941B2 (enExample)
KR (2) KR100966667B1 (enExample)
AT (1) ATE452888T1 (enExample)
AU (1) AU2003291337B2 (enExample)
CA (1) CA2505368C (enExample)
CY (1) CY1110295T1 (enExample)
DE (1) DE60330703D1 (enExample)
DK (1) DK1562941T3 (enExample)
ES (2) ES2336911T3 (enExample)
PT (1) PT1562941E (enExample)
SI (1) SI1562941T1 (enExample)
WO (1) WO2004043954A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CN101088998A (zh) * 2002-11-07 2007-12-19 科桑生物科学公司 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
EP2135868A1 (en) * 2002-11-07 2009-12-23 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same
BRPI0408891A (pt) * 2003-03-28 2006-04-11 Kosan Biosciences Inc dispositivos, métodos, e composições para prevenir restenose
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
EP2094721B1 (en) 2006-12-14 2018-02-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US7981999B2 (en) * 2007-02-23 2011-07-19 Aileron Therapeutics, Inc. Triazole macrocycle systems
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
PL2603600T3 (pl) 2010-08-13 2019-06-28 Aileron Therapeutics, Inc. Makrocykle peptidomometyczne
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132711C (en) 1992-03-23 2005-02-08 Aquilar Rahman Liposome encapsulated paclitaxel and a method of using the same
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
JP4644364B2 (ja) 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19954229A1 (de) * 1999-11-04 2001-05-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907480A1 (de) * 1999-02-11 2000-08-17 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
EP1185301A1 (en) 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
DK1652926T3 (da) 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030176368A1 (en) * 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2135868A1 (en) * 2002-11-07 2009-12-23 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same

Also Published As

Publication number Publication date
JP5679757B2 (ja) 2015-03-04
ATE452888T1 (de) 2010-01-15
WO2004043954A3 (en) 2004-11-18
KR100996996B1 (ko) 2010-11-25
PT1562941E (pt) 2010-01-25
DK1562941T3 (da) 2010-04-19
WO2004043954A2 (en) 2004-05-27
CA2505368A1 (en) 2004-05-27
KR20050084959A (ko) 2005-08-29
EP1562941B1 (en) 2009-12-23
EP1562941A2 (en) 2005-08-17
US20090186927A1 (en) 2009-07-23
EP2135868A1 (en) 2009-12-23
KR100966667B1 (ko) 2010-06-29
AU2003291337A1 (en) 2004-06-03
CY1110295T1 (el) 2015-01-14
SI1562941T1 (sl) 2010-05-31
JP2013213054A (ja) 2013-10-17
DE60330703D1 (de) 2010-02-04
ES2436296T3 (es) 2013-12-30
JP4641941B2 (ja) 2011-03-02
ES2336911T3 (es) 2010-04-19
US20040152708A1 (en) 2004-08-05
AU2003291337B2 (en) 2010-09-09
EP2135867B1 (en) 2013-09-25
EP2135867A1 (en) 2009-12-23
JP2006510743A (ja) 2006-03-30
JP2011006480A (ja) 2011-01-13
KR20100018075A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
CA2505368C (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same
JP2006510743A5 (enExample)
EP1089998B1 (en) Epothilone derivatives and their synthesis and use
US6489314B1 (en) Epothilone derivatives and methods for making and using the same
US20020045609A1 (en) Epothilone derivatives and methods for making and using the same
JP2004500388A (ja) エポチロン、その中間体およびその類似体の合成
US20020058286A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US20020156110A1 (en) Epothilone compounds and methods for making and using the same
CN101519404B (zh) 15环噻酮衍生物及其制备方法与应用
WO2002080846A2 (en) Epothilone derivatives and methods for making and using the same
US20020058817A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US20030023082A1 (en) Epothilone derivatives and methods for making and using the same
US20030134883A1 (en) 14-Methyl-epothilones
US7070964B2 (en) Epothilone compounds and methods for making the same
CN1330648C (zh) 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
HK1102439A (en) Epothilone derivatives and their synthesis and use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191107